Dopamine and D1 agonists and NE all increase phosphatidyl inositol-specific phospholipase C (PLC) activity, but whereas dopamine produces a natriuresis, NE has an antinatriuretic effect. To Invest. 1995.95:304-308.)
Introduction
Dopamine can inhibit transport by cAMP-dependent and -independent mechanisms (1) (2) (3) (4) (5) . We and others have reported that dopamine and D, agonists can inhibit Na+/H+ exchange activity by a guanine nucleotide binding protein (G-protein) '-dependent/cAMP-independent mechanism; in these experiments, Na+/H+ exchange activity was inhibited even when formation of cAMP/protein kinase A was prevented (1, 2). Another cAMP-independent pathway of sodium transport inhibition may be via a putative dopamine receptor, which thus far has not been cloned (6, 7) . This putative receptor shares some properties with the DIA and DiB receptors, since all are blocked by D1 antagonists (e.g., SCH 23390 and SKF 83742) and stimulated by DI agonists (e.g., fenoldopam). This receptor, unlike the cloned DIA and DIB receptors that are linked to stimulation of adenylyl cyclase, is linked to the stimulation of phosphatidyl inositol-specific phospholipase C (PLC) and not to adenylyl cyclase (6) (7) (8) (9) (10) (11) . Dopamine has also been demonstrated to inhibit Na+/K' ATPase activity by stimulating PLC activity (4, 5) . However, angiotensin II and a-adrenergic agonists, which also stimulate PLC activity, increase Na1/K+ ATPase and Na+/H+ exchange activity (2, [12] [13] [14] [15] [16] [17] .
PLC isoforms have been linked to specific receptors, Gproteins, and tyrosine kinases (18, 19) . For example, stimulation of G-protein linked cell surface receptors such as a-adrenergic and serotonin receptors has been linked to increased PLCf31 without changes in PLCy1 activity (20) (21) (22) (23) . The PLC isoform linked to angiotensin II is not clear but it is not PLC-y (24) .
However, the linkage of these neurotransmitters to PLC isoforms was studied in reconstituted systems and not in their innate environment. The linkage of DI dopamine receptors to PLC isoforms has not been reported. We therefore examined in the kidney the linkage of DI dopamine receptors to PLC isoforms and compared it with NE to determine if differential regulation of PLC isoforms by catecholamines occurs.
Methods
Rats were maintained on standard rat chow until the day of experiment. The rats were anesthetized with pentobarbital (50 mg/kg body wt, i.p.), placed on a heated table to maintain rectal temperature between 36 and 370C, and tracheotomized (PE-240). Anesthesia was maintained by the infusion of pentobarbital at 0.8 mg/100 g body wt per h. Catheters (PE-50) were placed into the external jugular and femoral veins and left femoral artery. Systemic arterial pressure was monitored electronically using Cardiomax II (Columbus Instruments, Columbus, OH). Suprapubic cystostomy was performed for urine collection. Fluid losses during surgery were replaced with 5% albumin at 1% body weight over 30 min. The jugular vein was cannulated (PE-50) for the infusion of normal saline solution at a rate of 5 ml/ 100 g body wt for 30 min, followed by a rate of 1.8 ml/ 100 g body wt per h until the end of the experiment. After an equilibration period of 120 min, the first 60-min urine collection for clearance determinations was begun and served as the baseline period. The first group of rats was divided into those receiving normal saline (1.2 ml/h i.v.), the DI agonist fenoldopam (5 ag/kg per minute at 1.2 ml/h i.v.), and the DI/D2 agonist pramipexole (5 ag/kg per min at 1.2 ml/h i.v.). The second group of rats was divided into those receiving normal saline (1.2 mi/h i.v.), the D I/D2 agonist pramipexole (5 pIg/kg per min at 1.2 ml/h i.v.), the preferential D, antagonist SKF 83742 (5 ,ug/kg per min at 1.2 ml/h i.v.), or a combination of pramipexole and SKF 83742 (each at 5 pg/kg per min at 1.2 ml/h i.v.). In both of the above groups of rats, the vehicle-and drug-treated animals were always studied at the same time.
In a third group of rats, the right suprarenal artery was catheterized and normal saline was infused at 0.2 ml/h. After the first 60-min collection period for clearance determinations, the In this third group of rats, urine was collected from the right and left ureters. After 3-4 h, during which time the natriuresis (dopamine agonist) or antinatriuresis (NE) was expected to be evident (and verified subsequently by actual measurements of sodium excretion), the kidneys were removed for analyses. The uninfused left kidney served as a concurrent control for the right infused kidney.
Preparation of and purification of cytosol and membranes from kidney. The kidney cortex was separated from the medulla and homogenized (1 g/2 ml) in (mM) 50 Tris-Cl, pH 7.4, containing 1 EDTA, 5 PMSF, 0.1 diisopropyl fluorophosphate, 0.1 DTT, 100 NaCI, and 250 sucrose (buffer A) using a polytron homogenizer. The homogenate was centrifuged at 100,000 g for 30 min at 40C. The supernatant represented the cytosol fractions. The particulate fractions were then washed three times, first with 50 mM Tris-Cl, pH 7.4, 1 mM EDTA, 2 M KCl, second with 20 mM Tris-HCl, 1 mM EDTA, and third with buffer A. The protease inhibitors trypsin inhibitor, leupeptin, and aprotinin (10 pg/ ml) were added to all the buffers. The final pellets were then resuspended in 4 ml of 50 mM Tris-HCl, pH 7.0, containing 1% sodium cholate and stirred overnight on ice. After centrifugation at 100,000 g for 30 min, the supernatant was obtained and designated as crude extract of membrane PLC. The PLC in the cytosol and membrane fractions were partially purified according to the methods of Ryu et al. (25) and Carter et al. (26) . In brief, the pH of cytosol fractions was adjusted to 5.0 by 1 M acetic acid with stirring on ice for 30 min. The precipitates were collected by centrifugation at 15,000 rpm for 30 min and dissolved in the buffer A. The membrane fractions, extracted by 1% sodium cholate, were mixed with DEAE cellulose (2 ml/sample) on ice for 1 h. Thereafter, the mixture was poured onto minicolumns (2 ml). After washing the unbound proteins, the columns were eluted with buffer A containing 1 10 or 150 mM KCl. PLC#,I is eluted by 110 mM KCl but not by 150 mM KCl (25) . The eluates were concentrated by Amicon (Beverly, MA) concentrators. The protein concentrations of the samples were determined by the Bradford method (27) .
Measurement of PLC activity. The 110-and 150-mM KCl eluates and cytosol were assayed for PLC activity according to the method of Nishibe et al. (28) . In brief, the assay was performed in 50 ,ul of reaction mixture containing 40,000 cpm of phosphatidyl inositol-4,5- PIP2-hydrolyzing radioactivity was determined by liquid scintillation counting. The results of the activity were expressed as cpm/mg protein/min.
Immunoblot analysis. The partially purified cytosol and membranes were mixed with Laemmli sample buffer, boiled for 5 min, and subjected to electrophoresis on 7.5% SDS-PAGE. Rat brain cytosol was used for positive control. The proteins separated by SDS-PAGE were electrophoretically transferred to nitrocellulose membranes. The transblot sheets were blocked with 1% nonfat dry milk in 10 mM Tris-HCl, pH 7.5, containing saline and 0.05% Tween-20 (TBST buffer), and incubated with diluted monoclonal antibodies to PLC isoforms for 2 h at room temperature or overnight at 4°C. The sheets were washed with TBST buffer three times and then incubated with diluted secondary antibody peroxidase-conjugated affinity-purified goat anti-mouse IgG for 2 h at room temperature. The immunoblots were extensively washed and developed with a solution containing 5 mg of 3,3'-diaminobenzidine and 3.3 ,l of 30% hydrogen peroxide in 10 ml of 50 mM Tris-Cl, pH 7.5. In some cases, enhanced chemiluminescence (ECL) Western blot detection reagents (RPN 2106) were used, and the immunoblots were examined after exposed to Kodak film. The immunoblots were quantified using Quantiscan (Biosoft, Ferguson, MO). The percent area of each blots was quantified with the total area arbitrarily set at 100%.
We obtained monoclonal antibodies for the PLC isoforms of proven specificity that have been used and characterized by others (29, 30) . In our studies, the absence of cross-reactivity was easily determined since the molecular size of PLC#,I (150 kD) was different from that of PLCyj 0.90+0.27%, n = 6). These increases were significant compared with basal values or with vehicle-treated rats (P < 0.05 ANOVA for repeated measures, Scheffe's test). Mean arterial pressure and creatinine clearance did not change. The DI antagonist, SKF 83742, alone (n = 6) did not affect mean arterial pressure or creatinine clearance; however, it did block the diuretic and natriuretic effect of pramipexole. These changes are similar to those reported from our laboratory and those of others (31, 32) . The right intrarenal arterial infusion of NE infusion, as expected, decreased absolute sodium excretion (2385+±794 to 1574+836, n = 5) (P < 0.05 ANOVA for repeated measures); fractional sodium excretion was slightly but not significantly decreased (1.28+0.40 vs. 0.90+0.38%), probably due to a slight but insignificant fall in glomerular filtration rate.
Immunoblot analysis of PLCs in renal cortical cytosol and membrane fractions. After administration of the drugs outlined above, kidney cortex or medulla was prepared as described in Methods. The partially purified cytosol and membranes were subjected to 7.5% of SDS-PAGE gels. We found that at least three PLC isozymes (PLC,/1, PLCyI, and PLC61) were expressed in kidney, and their molecular masses were the same as those reported for the rat brain, 150, 145, and 85 kD, respectively (not shown). The intravenous infusion of pramipexole, a DI/D2 agonist, fenoldopam, a DI agonist, or vehicle was associated with increased expression of PLCI1 and PLCyI in renal cortical cytosolic fractions. In contrast, in renal cortical membranes, the expression of PLCI1 increased but the expression of PLCyI decreased (Fig. 1, A and B) ; PLC6 was unchanged (data not shown). There were no changes in any of the PLC isoforms tested in renal medullary tissues (data not shown).
We chose to examine further the effect on PLC isoforms of the DI /D2 agonist, pramipexole, since dopamine has effects on both the DI and D2 receptors (8) . Pramipexole was chosen over dopamine, however, since the latter has actions on nondopamine receptors as well ( 8, 31 ) . To determine specificity of the pramipexole effect, concurrent studies were performed using the do- whereas it decreased the expression of PLCyj in renal cortical membranes; the expression of both PLC isoforms was increased in cytosolic fraction (Fig. 2, A and B) , confirming the studies shown in Fig. 1, A and B. The changes were blocked by the antagonist SKF 83742, which by itself had no effect (Fig. 2, A and B). To minimize variability of the experimental procedures, sets of vehicle-and drug-treated rats were always studied concurrently. Determination ofPLC activity. To determine if the changes in PLC isoform protein expression were associated with changes in enzyme activity, additional studies were performed. To minimize extrarenal influences, fenoldopam was infused into the right renal artery; the left kidney served as control. Western blotting of the 110-and 150-mM KCl eluate confirmed the studies of Ryu et al. (25) , showing that 110 mM KCl eluted PLC61 and was not detectable in the 150-mM KCl eluate; PLCy1 was found in both 110-and 150-mM KCl eluate (Fig.  3, A and B) . Compared with the noninfused left kidney, in renal cortical membranes fenoldopam increased PLC activity (29% ,  Table I ) of the 10-mM KCl eluate. This increase in PLC activity induced by fenoldopam represents PLC/3 activity since PLC#, expression increased 178%, whereas PLCyj expression decreased (-53%) in this eluate (Fig. 3) . PLC activity in the 150-mM KCI eluate, which represents PLCy activity (PLCf, Immunoblot of cytosol and membrane fraction from rat kidney cortex using monoclonal antibodies against PLCfi (A) or PLCy1 (B) after 3-4 h of intravenous infusion of the D1/D2 agonist pramipexole, the full D1, partial D2 antagonist SKF 83742, the co-infusion of pramipexole and SKF 83742, or vehicle (control group). Densitometric analysis of immunoblots shows that compared with vehicle-treated rats, pramipexole increased PLC(,3 in cytosol and membrane; this agonist also increased PLCyj in cytosol but decreased it in membranes. The effects were blocked by SKF 83742, which by itself had no effect (n = 4-5 per group). Data are means±SE. *P < 0.05 vs. control, ANOVA and Scheffe's test.
was not detectable in this fraction), was decreased by fenoldopam (-42%). The increase in PLC3 activity associated with fenoldopam in the 110-mM KC1 eluate is an underestimate since PLCy activity, which decreased, contributed 40% of PLC protein in this fraction. In agreement with previous reports using reconstituted cell systems (reviewed in reference 22), in renal tubular membranes, NE also increased PLC,6 expression (not shown) and activity but had no effect on PLCy activity (Table  II) . PLC activity in cytosol was increased by both fenoldopam and NE.
Discussion
In renal cortical homogenates, dopamine and DI agonists (DI receptors in the kidney are most abundant in proximal tubules) can stimulate phosphoinositide hydrolysis by activation of phosphatidyl inositol-specific PLC (6, 7). The ability of dopamine to initiate phosphoinositide hydrolysis has been confirmed in the kidney (2, 4, 33), brain striatum (11, 34) , and the retina (10) . Furthermore, cholera and pertussis toxin-insensitive Gproteins were involved (7) .
Several PLC enzymes have been purified, molecularly cloned, and sequenced (18, 19) . These isoforms of PLC have been classified into three families, PLCP, PLCy, and PLC6 with several members in each (e.g., PLC/31, PLC62, PLC,63).
PLC has been linked to pertussis sensitive and insensitive Gproteins and tyrosine kinases (18, 19, 23, 35) . The Gq family of G-proteins, which are pertussis toxin insensitive, have been linked to activation of PLC/,3 whereas tyrosine kinases activate PLCy>' (36, 37) . The receptors that activate PLC via Gq include thromboxane A2, bradykinin, angiotensin H, histamine, vasopressin, acetylcholine muscarinic (M1, M3, and M), a1-adrenergic (aiB and aic), a2-adrenergic (a2A), and serotonergic (5-HT1c) receptors (19, 20, 22, 28, (38) (39) (40) (41) (42) . PLC/3 isoforms (PLC33 > PLC32 > PLCf31) can also be activated by G-protein i/3y-subunits independently of a-subunits (43) . However, these studies were performed in reconstituted systems. The link- (20) .
Besides linkage of DI-like receptors to PLC via pertussisinsensitive G-proteins, one of the DI receptors linked to stimulation of adenylyl cyclase (DIA) also stimulated phosphoinositol hydrolysis via cholera toxin-sensitive G-proteins in murine fibroblasts transfected with the human or rat DIA cDNA (44 
